Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNVC - NanoViricides, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: andy71 who wrote (10337)	5/29/2018 1:34:36 PM
From: donpat	Read Replies (3) \| Respond to of 12873

If NNVC performs as intended it will trade at $100 to $1000/share..conservatively. That's for sure. I've never been wrong.

To: andy71 who wrote (10337)	5/30/2018 12:38:50 PM
From: HardToFind	Respond to of 12873

I'm not buying right now because the company has numerous problems that appear to be coming to a head. These problems start with the low cash position, are followed by the lack of a publicly stated schedule, and end with the terrible deal that shareholders have with Diwan & TheraCour. Boniuk notwithstanding, I don't know what venture finance person worth his salt wants a piece of the deal NNVC shareholders have as it sits today. Normally I'd expect to see that the company has substantially reduced risks since the last round of equity raises. What I see instead is Diwan attempting to build a company and expand the market without putting to rest a lot of the risks. The top three risks I see are: Management - the perceived inability to execute to a publicly stated schedule and milestones Drug Production - the question of what drug material we can produce in what quantities to what standards and at what cost Regulatory Approval Process - which starts with getting something into human trials This isn't a comprehensive list, but is a good place to start. So I'd like to at least see how the capital raise goes.